Companies: 49,246 Total Market Cap: 132441797263938.02

Galapagos NV

NASDAQ: GLPG

Healthcare Biotechnology

Rank #6345

Market Cap 1.83 B

Volume 274,249

Price 28.70

Change (%) 2.83%

Country or region

Belgium

Galapagos NV's latest marketcap:

1.83 B

As of 05/20/2025, Galapagos NV's market capitalization has reached $1.83 B. According to our data, Galapagos NV is the 6345th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap	1.83 B
Revenue (ttm)	311.49 M
Net Income (ttm)	-183,247,946
Shares Out	65.84 M
EPS (ttm)	-2.78
Forward PE	0.00
Ex-Dividend Date	n/a
Earnings Date	04/23/2025

Market Cap Chart

Data Updated: 05/20/2025

Galapagos NV's yearly market capitalization.

Galapagos NV has seen its market value drop from $2.32 B to $1.83 B since 2015, representing a total decrease of 21.14% and an annual compound decline rate (CAGR) of 2.50%.

Date	Market Cap	Change (%)
05/20/2025	$1.83 B	-7.93%
12/31/2024	$1.81 B	-32.28%
12/29/2023	$2.68 B	-8.14%
12/30/2022	$2.91 B	-19.35%
12/31/2021	$3.61 B	-43.56%
12/31/2020	$6.40 B	-43.18%
12/31/2019	$11.27 B	141.07%
12/31/2018	$4.67 B	7.74%
12/29/2017	$4.34 B	72.91%
12/30/2016	$2.51 B	8.12%
12/31/2015	$2.32 B

Company Profile

Galapagos NV Overview

Galapagos NV is a biotechnology company specializing in the development of innovative medicines, with a primary focus on oncology and immunology. The company operates mainly in the United States and Europe.

Pipeline Products

GLPG3667: Completed Phase 1b trial.
GLPG5101: A CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase 1/2 trial for relapsed/refractory non-Hodgkin lymphoma.
GLPG5201: A CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase 1/2 trial for relapsed/refractory chronic lymphocytic leukemia.
GLPG5301: A BCMA CAR-T product candidate manufactured at point-of-care, currently in Phase 1/2 trial for relapsed/refractory multiple myeloma.

Collaborations

The company has strategic collaboration agreements with:

Gilead Sciences, Inc.
AbbVie S.à r.l.

Company Background

Founded in 1999, Galapagos NV is headquartered in Mechelen, Belgium.

Frequently Asked Questions

As of 05/20/2025, Galapagos NV (including the parent company, if applicable) has an estimated market capitalization of $1.83 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Galapagos NV global market capitalization ranking is approximately 6345 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region	Belgium
Founded	1999
IPO Date	05/06/2005
Employees	704
CEO	Paulus Stoffels
Sector	Healthcare
Industry	Biotechnology
Address	Generaal De Wittelaan L11 A3 Mechelen, 2800 Belgium
Website	https://www.glpg.com